Figure 4 from Determinants and Effectiveness of Extending the Duration of Adjuvant Hormone Therapy beyond 5 Years in Patients with Breast Cancer

<p>Disease-free survival and overall survival in patients who extended therapy and those who did not. <b>A</b> and <b>B,</b> Disease-free survival (<b>A</b>) and overall survival (<b>B</b>). Note: HR was adjusted for age at diagnosis, calendar pe...

Description complète

Enregistré dans:
Détails bibliographiques
Auteur principal: Erwei Zeng (14958443) (author)
Autres auteurs: Wei He (14958446) (author), Arvid Sjölander (14958449) (author), Jenny Bergqvist (14958452) (author), Kamila Czene (14958455) (author)
Publié: 2025
Sujets:
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
Description
Résumé:<p>Disease-free survival and overall survival in patients who extended therapy and those who did not. <b>A</b> and <b>B,</b> Disease-free survival (<b>A</b>) and overall survival (<b>B</b>). Note: HR was adjusted for age at diagnosis, calendar period of cancer diagnosis, tumor size, lymph node status, tumor grade, progesterone receptor status, chemotherapy, radiotherapy, Charlson Comorbidity Index at extension, education, and income at diagnosis.</p>